JPWO2020006385A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020006385A5 JPWO2020006385A5 JP2020572903A JP2020572903A JPWO2020006385A5 JP WO2020006385 A5 JPWO2020006385 A5 JP WO2020006385A5 JP 2020572903 A JP2020572903 A JP 2020572903A JP 2020572903 A JP2020572903 A JP 2020572903A JP WO2020006385 A5 JPWO2020006385 A5 JP WO2020006385A5
- Authority
- JP
- Japan
- Prior art keywords
- macrophages
- activity
- monocytes
- amount
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692463P | 2018-06-29 | 2018-06-29 | |
| US62/692,463 | 2018-06-29 | ||
| US201962810683P | 2019-02-26 | 2019-02-26 | |
| US62/810,683 | 2019-02-26 | ||
| US201962857199P | 2019-06-04 | 2019-06-04 | |
| US62/857,199 | 2019-06-04 | ||
| US201962867532P | 2019-06-27 | 2019-06-27 | |
| US62/867,532 | 2019-06-27 | ||
| PCT/US2019/039773 WO2020006385A2 (en) | 2018-06-29 | 2019-06-28 | Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529753A JP2021529753A (ja) | 2021-11-04 |
| JP2021529753A5 JP2021529753A5 (https=) | 2022-07-05 |
| JPWO2020006385A5 true JPWO2020006385A5 (https=) | 2022-07-05 |
Family
ID=68985243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572903A Pending JP2021529753A (ja) | 2018-06-29 | 2019-06-28 | 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210189342A1 (https=) |
| EP (1) | EP3813881A4 (https=) |
| JP (1) | JP2021529753A (https=) |
| KR (1) | KR20210040948A (https=) |
| CN (1) | CN113164589A (https=) |
| AU (1) | AU2019293600A1 (https=) |
| BR (1) | BR112020026386A2 (https=) |
| CA (1) | CA3103154A1 (https=) |
| TW (1) | TW202023629A (https=) |
| WO (1) | WO2020006385A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3866818B1 (en) * | 2018-10-19 | 2025-07-23 | Regenics AS | Use of fish egg cellular extractt for wound healing |
| US12006345B2 (en) | 2019-02-21 | 2024-06-11 | Xencor, Inc. | Untargeted and targeted IL-10 Fc-fusion proteins |
| CA3141334A1 (en) | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| KR20220042128A (ko) * | 2019-06-27 | 2022-04-04 | 베르조 테라퓨틱스, 아이엔씨. | 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도 |
| CA3142838A1 (en) * | 2019-06-27 | 2020-12-30 | Verseau Therapeutics, Inc. | Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| US11987612B2 (en) | 2019-11-04 | 2024-05-21 | Alector Llc | Siglec-9 ECD fusion molecules |
| JP2023508498A (ja) * | 2019-12-30 | 2023-03-02 | ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | １型糖尿病を処置するためのマクロファージの膵臓内ｍ２極性化 |
| WO2021154709A1 (en) * | 2020-01-28 | 2021-08-05 | Nanotomer, Inc. | Clathrin-chimeric antibody receptor constructs for immune cell activation therapy in vivo |
| US11642629B2 (en) * | 2020-03-20 | 2023-05-09 | Saudi Arabian Oil Company | Multi-layer composite gas separation membranes, methods for preparation, and use |
| CN115667544A (zh) * | 2020-03-27 | 2023-01-31 | 无界生物公司 | 鉴定染色体外dna特征的方法 |
| JP7560893B2 (ja) | 2020-04-20 | 2024-10-03 | デュオジェニック ステムセルズ コーポレーション | 修飾マクロファージ、組成物およびその使用 |
| WO2021263115A1 (en) * | 2020-06-26 | 2021-12-30 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment |
| CN112837306B (zh) * | 2021-02-20 | 2022-11-22 | 薛竟宜 | 基于深度学习和中智理论的冠状动脉病变功能学定量方法 |
| CN113884682B (zh) * | 2021-04-30 | 2023-07-21 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 检测巨核细胞或血小板表面标志分子的产品在制备检测感染的产品中的用途 |
| WO2023004235A1 (en) * | 2021-07-23 | 2023-01-26 | University Of Florida Research Foundation, Incorporated | Controlling pro-inflammatory macrophage phenotype through biofunctional hydrogel design |
| CN113897397B (zh) * | 2021-09-30 | 2024-04-02 | 中南大学 | 一种基于DNAzyme调控基因编辑的方法 |
| CN114010666B (zh) * | 2021-10-22 | 2024-05-07 | 上海交通大学 | 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用 |
| CN113913507A (zh) * | 2021-10-29 | 2022-01-11 | 温州医科大学附属第一医院 | Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用 |
| CN114214237B (zh) * | 2021-12-23 | 2023-06-16 | 南京大学 | 一种洗脱细胞表面吸附纳米颗粒的方法 |
| CN115029473B (zh) * | 2022-06-21 | 2024-06-18 | 湖北省药品监督检验研究院 | 一种基于mlpa技术对中药材桃仁与苦杏仁进行鉴别的方法 |
| CN115739182B (zh) * | 2022-11-17 | 2024-01-16 | 合肥机数量子科技有限公司 | 含单分散铁原子的过氧化物模拟酶及其制备方法和用途 |
| WO2024189098A1 (en) * | 2023-03-13 | 2024-09-19 | Iomx Therapeutics Ag | Platform technology for the identification of modulators of immune effector cell function |
| CN116403649A (zh) * | 2023-03-17 | 2023-07-07 | 中山大学附属第六医院 | 一种igsf6基因在免疫治疗治疗系统中的应用 |
| AU2024237943A1 (en) * | 2023-03-20 | 2025-10-09 | The Regents Of The University Of California | Methods and materials for treating cancer |
| CN117159495A (zh) * | 2023-08-16 | 2023-12-05 | 北京大学 | 脂质纳米颗粒及其应用 |
| TWI873056B (zh) * | 2024-07-01 | 2025-02-11 | 國立成功大學 | 採用影像分割技術的胃內視鏡影像分析方法與電腦系統 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1972703A (zh) * | 2004-03-30 | 2007-05-30 | 丹麦皇家兽医和农业学院 | 通过阻断和检测蛋白酶抑制剂改进癌症的治疗和癌症治疗效率的预测 |
| WO2009140623A2 (en) * | 2008-05-15 | 2009-11-19 | Selexys Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
| WO2011143411A1 (en) * | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy for traumatic brain injury |
| US9139652B2 (en) * | 2011-10-21 | 2015-09-22 | Transgene Sa | Method for increasing M1 macrophages in a patient |
| WO2015077401A1 (en) * | 2013-11-20 | 2015-05-28 | Drexel University | Compositions and methods for macrophage conversion |
| US20170306042A1 (en) * | 2014-08-29 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis |
| US20160200815A1 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| GB201611535D0 (en) * | 2016-07-01 | 2016-08-17 | King S College London | Methods and compositions for treating cancer with siglec-9 activity modulators |
| EP3568159A4 (en) * | 2017-01-11 | 2020-08-05 | Bristol-Myers Squibb Company | PSGL-1 ANTAGONISTS AND THEIR USES |
-
2019
- 2019-06-28 JP JP2020572903A patent/JP2021529753A/ja active Pending
- 2019-06-28 TW TW108122978A patent/TW202023629A/zh unknown
- 2019-06-28 CN CN201980056952.6A patent/CN113164589A/zh active Pending
- 2019-06-28 EP EP19825130.8A patent/EP3813881A4/en active Pending
- 2019-06-28 WO PCT/US2019/039773 patent/WO2020006385A2/en not_active Ceased
- 2019-06-28 KR KR1020217002262A patent/KR20210040948A/ko not_active Ceased
- 2019-06-28 BR BR112020026386-9A patent/BR112020026386A2/pt unknown
- 2019-06-28 CA CA3103154A patent/CA3103154A1/en active Pending
- 2019-06-28 AU AU2019293600A patent/AU2019293600A1/en not_active Abandoned
- 2019-06-28 US US17/252,379 patent/US20210189342A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529753A5 (https=) | ||
| JPWO2020006385A5 (https=) | ||
| Weng et al. | MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer | |
| Sato-Kaneko et al. | Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer | |
| Zhou et al. | Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib | |
| EP3082840B1 (en) | Methods and assays relating to circulating tumor cells | |
| EP2412825B1 (en) | Leukemia stem cell markers | |
| Wu et al. | Tumor cell–derived TGFβ1 attenuates antitumor immune activity of T cells via regulation of PD-1 mRNA | |
| US7776541B2 (en) | Psoriasin expression by breast epithelial cells | |
| CN103492590A (zh) | 循环生物标志物 | |
| Sakai et al. | Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients | |
| Chen et al. | SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production | |
| Sorrentino et al. | CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality | |
| Han et al. | Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma | |
| Wang et al. | HSP90AA1 is an unfavorable prognostic factor for hepatocellular carcinoma and contributes to tumorigenesis and chemotherapy resistance | |
| Wang et al. | Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis | |
| Furuya et al. | Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis | |
| EP2619328B1 (en) | Top2a inhibition by temozolomide useful for predicting gbm patient's survival | |
| CN118679266A (zh) | 对先天免疫激活剂的反应的转录生物标志物 | |
| Ying et al. | Exosomal miR-184 facilitates bladder cancer progression by targeting AKR1C3 and inducing immune escape via IRF2-CXCL10 axis | |
| JP2025003730A (ja) | 癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法 | |
| JP7677664B2 (ja) | 尿路上皮がんを検査する方法 | |
| US20240167098A1 (en) | Methods for predicting treatment outcome to checkpoint inhibitors in cancer | |
| JP2025509212A (ja) | 免疫療法に対する患者応答を予測するための方法 | |
| CN115558652A (zh) | 靶向n-乙酰基转移酶10在弥漫大b细胞淋巴瘤治疗中的应用 |